Bedrijfsoverzicht
Rein Therapeutics Inc. is a biopharmaceutical entity dedicated to developing therapeutic medicines aimed at addressing unmet medical needs within orphan pulmonary and fibrosis indications in the United States. The company operates within the Healthcare sector and specifically the Biotechnology industry, positioning itself to target specialized patient populations with rare or neglected conditions. As of the latest available data, the firm reports a market capitalization of $41.78M, generates no reported annual revenue, and maintains an operational workforce of 10 employees. These financial figures indicate that the company is in an early-stage development phase where capital is primarily allocated toward research and clinical trials rather than commercial revenue generation, a common characteristic for biotechnology firms with lead product candidates such as LTI-03 currently in Phase 1b clinical trials.
Financiële gezondheid
The company reports revenue of N/A for the trailing twelve months, with a net income of $-49,871,000 and an EBITDA of $-21,930,000. The substantial gap between the reported revenue figure and the significant net loss reveals a cost structure heavily weighted toward research and development expenses rather than cost of goods sold, which is typical for pre-revenue biopharmaceutical companies. Free cash flow stands at $-11,369,875, indicating that the company is burning cash to fund its operations and clinical programs, thereby limiting its immediate financial flexibility until future product approvals or partnership deals occur. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a standard presentation for entities that have not yet achieved commercial sales or have not yet recorded revenue in the reporting period. The balance sheet shows a cash position of $3.21M against $0 in debt, suggesting a conservative capital structure devoid of interest obligations but constrained by limited liquidity reserves. However, the current ratio of 0.70 indicates that the company's current liabilities exceed its current assets, signaling potential short-term liquidity pressure that must be managed through external financing or successful clinical milestones. Return on Equity is -139.9% and Return on Assets is -31.7%, metrics that reflect the negative returns generated by the company's capital base due to accumulated net losses and the absence of profitable operations to date.
Waarderingsbeoordeling
The trailing P/E ratio and forward P/E ratio are both listed as N/A, reflecting the company's status as a non-profitable entity where traditional earnings-based valuation metrics are not applicable. Consequently, the market prices the stock based on alternative metrics such as the price-to-book ratio of -1.46, which indicates a negative valuation relative to shareholders' equity, often seen in distressed or pre-revenue biotech stocks. Alternative valuation measures like the price-to-sales ratio and EV/EBITDA are also N/A or derived from negative earnings, with an EV/EBITDA of -3.81 highlighting the company's deep losses relative to enterprise value. The stock has traded between a 52-week high of $2.40 and a 52-week low of $1.02, with the current market price situated within this range, reflecting the high volatility typical of small-cap biotechnology equities. The beta value of 1.40 suggests that the stock is expected to exhibit price volatility that is 40% higher than the broader market, meaning price movements will likely be amplified during periods of market stress or rally.
Growth & Income
Revenue growth and earnings growth for the year-over-year period are both recorded as N/A due to the lack of historical revenue data and current profitability. Since the company does not generate positive earnings, it is not a dividend payer, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. As a non-dividend payer, the company reinvests any available cash flow, currently negative, into its core mission of advancing its pipeline rather than distributing income to shareholders. The overall growth and income profile is defined by a complete absence of current commercial revenue and dividends, relying entirely on the future potential of its clinical development programs to drive value creation. The company's financial trajectory is currently dependent on the successful progression of LTI-03 through Phase 1b trials and subsequent regulatory approvals to transition from a loss-making R&D stage to a revenue-generating commercial entity.